$EXEL News

Exelixis, Inc. (EXEL): Renaissance Technologies Likes This Stock

Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026

How The Exelixis (EXEL) Story Is Shifting As Wall Street Reworks Fair Value Targets

Exelixis, Inc. (EXEL) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June

Exelixis: Financial Performance Improves Faster Than Market Expectations

Exelixis Eyes CABO Growth as Zanzalintinib Readouts and Potential CRC Launch Near

Exelixis (EXEL): 12 Best Low Priced Growth Stocks to Invest In Now

Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types

GlobeFlex Exits NCR Atleos After Brink’s Buyout Deal

Exelixis, Inc. (EXEL) Presents at Stifel 2026 Targeted Oncology Virtual Forum Transcript

Exelixis, Inc. (EXEL) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Prediction: This Stock Could Double By 2031

EXELIXIS INC (NASDAQ:EXEL) Presents a Compelling Case for Value Investors

Exelixis, Inc. (EXEL) Presents at Bank of America Global Healthcare Conference 2026 Transcript

TD Cowen Sees Pipeline Growth Opportunities Supporting Exelixis, Inc. (EXEL) Outlook

Exelixis, Inc. 2026 Q1 - Results - Earnings Call Presentation

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May

Why Exelixis (EXEL) Is Up 9.0% After Strong Q1 2026 Earnings And New Buyback Program

HC Wainwright & Co. Maintains Buy on Exelixis, Raises Price Target to $56